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Abstract: Alzheimer’s disease (AD) is an incurable and highly debilitating condition characterized by
the progressive degeneration and/or death of nerve cells, which leads to manifestation of disabilities
in cognitive functioning. In recent years, the development of biosensors for determination of AD’s
main biomarkers has made remarkable progress, particularly based on the tremendous advances in
nanoscience and nanotechnology. The unique and outstanding properties of nanomaterials (such as
graphene, carbon nanotubes, gold, silver and magnetic nanoparticles, polymers and quantum dots)
have been contributing to enhance the electrochemical and optical behavior of transducers while
offering a suitable matrix for the immobilization of biological recognition elements. Therefore, optical
and electrochemical immuno- and DNA-biosensors with higher sensitivity, selectivity and longer
stability have been reported. Nevertheless, strategies based on the detection of multiple analytes still
need to be improved, as they will play a crucial role in minimizing misdiagnosis. This review aims to
provide insights into the conjugation of nanomaterials with different transducers highlighting their
crucial role in the construction of biosensors for detection of AD main biomarkers.
Keywords: nanomaterials; electrochemical; optical; immunosensor; DNA sensor; biosensor; gold
nanoparticles; carbon nanotubes; graphene; polymers
1. Introduction
Neurodegenerative diseases (NDDs), whose prevalence is rapidly escalating, mainly in association
with the increase of the elderly population, are a heterogeneous group of disorders characterized by
the progressive degeneration of the structure and function of the central and/or peripheral nervous
systems [1–3]. NDDs have become a major health problem for the world’s population, with a
tremendous financial impact associated with medical care for both families and society [4–6].
Alzheimer’s disease (AD) is the most common NDD, as well as the most common form of
dementia. Nowadays, this disease affects approximately 40 million people, but its numbers are
predicted to escalate in the upcoming decades [7–10]. AD pathophysiology involves a combination of
processes that ultimately lead to loss of synaptic integrity, effective neural connectivity and progressive
neurodegeneration [7,8,10,11]. It is believed that the accumulation of amyloid β protein (Aβ) in
extracellular deposits is the primary event that eventually drives the formation of intraneuronal
inclusions of hyperphosphorylated tau protein, both accompanied by processes of inflammation and
oxidative stress [7,8,10]. In addition, despite the presence of Aβ aggregates being considered the
key pathological hallmark of AD, studies have revealed that Aβ oligomers may be its most toxic
form, leading to synaptic dysfunction [7,8,12]. Clinical application of these biomarkers can be very
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challenging, as the most commonly reported cut-off values in cerebrospinal fluid (CSF) are 500–700 pg
mL−1 (110–155 pM) [13] and 195 pg mL−1 (4.3 pM) [14] for Aβ42 and tau protein, respectively. Moreover,
studies have also focused on understanding the genetic components that influence the risks and
outcomes of neurological disease identifying the isoform apolipoprotein E4 (ApoE4) as a major genetic
risk factor for AD and decreased age of onset, as well as recognizing the protective role of the isoform
ApoE2 against the disease [15–17].
During the last century, life expectancy has increased as a result of major improvements in
worldwide health. Nevertheless, this fact can also increase the prevalence of AD as the risk of
incidence of this disease increases dramatically with age which accentuates the need to develop new
methodologies for its treatment, diagnosis and prevention [2,6]. In this context, it is highly desirable
to develop multiplexed devices capable of screening various biomarkers simultaneously promoting
a rapid, low-cost and reliable diagnosis in addition to contributing to a better understanding of the
molecular mechanisms and cascade of events underlining the disease pathophysiology [18,19].
Over the last decade, the number of studies concerning the development of rapid and easy-to-use
platforms for the detection of analytes based on biosensing technology has significantly increased, as
these devices display a wide range of benefits, such as high sensitivity and selectivity without the need
for large sample volumes. A biosensor is defined by IUPAC as an integrated transducer-receptor device,
which combines a biological recognition element with a transducer capable of converting the biological
response into quantitative or semi-quantitative analytical information [20,21]. Accordingly, biosensors
can be classified in terms of their biological recognition elements and transduction principle [21–23].
Immunosensors and DNA sensors are affinity ligand-based biosensing devices that involve the
transduction of immunochemical reactions benefiting from the highly specific interaction between
antibody–antigen and DNA strands, respectively [21–25]. Development of biosensors with high
sensitivity through the enhancement of their active surface area, (electro)chemical activity and
conductivity or optical properties is one of the major challenges of the biosensing field [21,25–28].
This way, the use of nanomaterials has been regarded as a crucial parameter for enhancing biosensor
analytical performance. In fact, nanomaterials have now become an integral part of every biosensing
platform, promoting an increase in sensitivity, which is reflected in their capability to lower detection
limits by several orders of magnitude [21,25–28]. The introduction of nanomaterials into biosensing
platforms and the optimization of their interaction with biological recognition elements will contribute
to the development of highly sensitive and specific point-of-care technology (POCT). The aim of POCT
is the conception of high-performance devices with low system complexity, ensuring sensitive analysis
in non-laboratory and resource-limited settings with user-friendly equipment while minimizing the
analysis time [18,29,30].
The goal of this review is to present an overview of the most frequently used nanomaterials in the
development of immunosensors and DNA sensors for the quantification of AD biomarkers covering
the period from 2008 to 2018. In the following sections, the role of nanomaterials in the structure of
biosensors is critically discussed, while their interactions with biological recognition elements, the
strategy for transducing the bioaffinity event and the analytical performance of the biosensors are
highlighted. Finally, this review brings into focus future perspectives on the impact of nanomaterials
in AD biosensing.
The available scientific literature within the last decade (2008–2018) was searched in
the Thomson Reuters ISI Web of Knowledge, Science Direct, PubMed and Google Scholar
databases by combining at least two of the following keywords: biosensor/electrochemical
immunosensor/optical immunosensor/DNA sensor in conjunction with Alzheimer’s disease/Amyloid
beta/Tau protein/Apolipoprotein E.
2. Nanomaterials in Biosensing of Neurodegenerative Disease Biomarkers
In recent decades, novel modified transducers have been developed based on the unique properties
of nanoscale materials and the ability to tailor their size and structure. As a result of quantum-size
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effects, nanomaterials exhibit great electronic, mechanical, thermal and optical properties and are
recognized as one of the most attractive ways to promote the design of biosensors with enhanced
analytical performance [21,31–33]. Integration of nanomaterials into biosensors has been found to
improve the conductivity and catalytic activity of the transducer while favoring the immobilization of
a large amount of biological recognition elements, as a result of their high surface area, in addition to
improving the accessibility of specific analytes to these elements [26,28,31–34]. In fact, functionalization
of nanomaterials has contributed to the development of highly sensitive and selective bioassays and
biosensors for nucleic acids and proteins by integrating the biological recognition elements with
the components of the various transduction mechanisms [26,27,34,35]. In this regard, considerable
attention has been devoted to the immobilization of biological recognition elements as this aspect
will have an impact on detection sensitivity, reproducibility and robustness, among other analytical
parameters [25,27,33,36]. The performance of a biosensor is predominantly dependent on the binding
affinity and specificity of binding molecules, their coating density onto the transducer’s surface and,
finally and most importantly, the orientation of the biological recognition elements after immobilization,
which should retain their full biological activity by ensuring that its binding sections remain intact and
accessible while also providing an effective electronic connection between the redox active sites in the
biomolecules and the transducer’s surface [26,32,37–39].
The most frequently applied nanomaterials in the development of immunosensors and DNA
biosensors are carbon materials such as graphene and carbon nanotubes (CNTs), gold nanoparticles
(AuNPs) and polymers, all having unique and specific properties applicable in the development of
novel transduction schemes. Other nanomaterials such as silver (AgNPs) and magnetic nanoparticles,
dendrimers and quantum dots (QDs) are also used, but to a lesser extent. These nanomaterials have
most commonly been reported for the development of biosensors performing detection via sandwich
immunoassays/DNA assays or through direct detection (Figure 1).
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(A) sandwich assay with second ry antibodies conjugated with nanomaterials and without labels;
(B) sandwich assay with labeled secondary antibodies; (C) direct etection.
2.1. Carbon Nanomaterials
Carbon-based materials including CNTs, graphene, fullerenes, carbon fibers, graphene quantum
dots and carbon dots have been receiving a lot of attention in the development of biosensing
analytical tools [37,40–43], with CNTs [44–47] and graphene [48–50] being the most commonly
applied carbon nanomaterials for the development of biosensors for the detection of AD biomarkers
(Table 1). Although the specific characteristics of carbon nanomaterials vary between them, their
most prominent advantages are reflected in their electrochemical activity, electrical conductivity, large
surface area, high surface-to-volume ratio, ease of functionalization, biocompatibility and anti-fouling
effect [27,33,35,37,40,42].
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Table 1. Biosensors based on carbon nanomaterials for determination of Alzheimer’s disease
(AD) biomarkers.
Transducer DetectionTechnique Analyte Sample
Limit of Detection
(nM *) Ref.
Carbon Nanotubes
CNTs-MESFET/Au
strip/Antibodies
Electrical
conductance Aβ42 Human Serum 2.2 × 10−4 * [44]
GCE/SWCNTs-ABTS-PDDA/NKB DPV Cu
2+
Aβ42
Buffer, Blood and
Hippocampus of rats
Cu2+—40
Aβ42—0.11 *
[45]
GCE/MWCNTs/AuNPs/Gelsolin/
Analyte/AuNPs-Gelsolin-HRP DPV Aβ40/Aβ42
Buffer, CSF and brain
tissue of rats 0.028 [46]
Prism/Au/Antibodies/Analyte/
MWCNTs-secondary antibodies SPR Tau protein aCSF 0.125 [47]
Graphene
ITO/graphene-QDs/
curcumin/DNA probe
DPV and
Fluorescence
detection
ApoE4 DNA Buffer and Humanblood plasma
DPV—2.18 **
Fluorescence
detection—12.4 **
[48]
GCE/GSHs/DNA probe DPV ApoE DNA Buffer 1 × 10−5 [49]
FET/rGO/Antibodies Impedance Aβ Buffer 1 × 10−6 [50]
* Value expressed in µg mL−1/ng mL−1/pg mL−1 and converted to nM. ** The results were not possible to convert
into molar units, and are thus displayed in pg mL−1. aCSF, Artificial cerebrospinal fluid; CNTs-MESFET, Carbon
nanotubes film-based metal semiconductor field effect transistor; CSF, Cerebrospinal fluid; DPV, Differential pulse
voltammetry; FET, Field effect transistor; GCE, Glassy carbon electrode; GSHs, Mesoporous graphene silica hybrids;
HRP, Horeseradish peroxidase; ITO, Indium tin oxide; MWCNTs, Multi-walled carbon nanotubes; NKB, Neurokinin
B; QDs, Quantum dots; rGO, Reduced graphene oxide; SPR, Surface plasmon resonance; SWCNTs-ABTS-PDDA,
2,2′-azinobis-(3-ethylbenzothiazoline-6-sulphonate)-poly(diallyldimethylammonium chloride)-bi functionalized
single-walled carbon nanotubes composite.
2.1.1. Carbon Nanotube-Based Biosensors
CNTs are cylindrical large molecules consisting of a hexagonal arrangement of hybridized carbon
atoms, which can be classified as single-walled carbon nanotubes (SWCNTs), composed of a single
graphite sheet rolled into a seamless hollow nanoscale tube, and multi-walled carbon nanotubes
(MWCNTs), characterized by the presence of multiple concentric tubes encircling one another [41,51,52]
(Figure 2). SWCNTs present a diameter in the range of 0.4–2 nm, while MWCNTs, depending on
the number of layers, can display a diameter in the range of 2–100 nm, with the distance between
each layer being approximately 0.34 nm [26,33,41,52–57]. Since their discovery in 1991 [58], they
have increasingly attracted research interest due to their high surface-to-volume ratio, exceptional
electronic properties, and the presence of edge-plane-like defects which make them very interesting for
biosensing applications [26,33,41,52,56,59]. In addition, another major advantage of CNTs is that they
can be easily functionalized with different chemical groups through covalent and non-covalent bonds,
which will further promote the immobilization of biomolecules or organic molecules [26,33,37,56].
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Figure 2. Structure of single-walled carbon nanotubes (SWCNTs) (A) and multi-walled carbon
nanotubes (MWCNTs) (B) (Reproduced with permission from [57]. Elsevier, 2010).
Oh et al. [44] developed a SWCNTs film-based biosensor with a metal semiconductor field effect
transistor structure (CNTs-MESFET) (Figure 3). A gold strip was deposited in the middle of the
CNTs channel, leading to the formation of a potential energy barrier (Schottky barrier) between both
materials [44]. This way, any changes in the CNTs channel covered with the gold strip would cause a
variance in the CNTs channel conductance, enabling the detection of the target analytes in real-time.
In this work, antibodies were immobilized on the gold surface after its functionalization with Escherichia
coli outer membrane with autodisplayed z-domains of protein A. By controlling the orientation of
antibodies upon their immobilization, the authors were able to attain higher sensitivities while also
achieving effective blocking towards unspecific binding, which was mainly attributed to the highly
negative charge of the outer membrane. In this way, the CNT-MESFET biosensor enabled real-time
detection of Aβ42 at levels as low as 1 pg mL−1 in human serum, while a linear relation was observed
in the range of 10−12–10−9 g mL−1 [44].
In a different work, Yu et al. [45] used SWCNTs to develop a ratiometric electrochemical
biosensor for the simultaneous determination of Cu2+ and Aβ based on a glassy carbon electrode
(GCE). To produce a stable colloidal suspension and favor the stability and electron transfer
of CNTs, SWCNTs were functionalized with poly (diallyldimethylammonium chloride) (PDDA)
and 2,2′-azinobis-(3-ethylbenzothiazoline-6-sulphonate) (ABTS) [45]. A homogeneous and dense
distribution of surface functional groups was achieved by the non-covalent functionalization of SWCNTs
with PDDA, which revealed itself to be essential for further assembly of negatively charged ABTS
and recognition elements. The inclusion of ABTS enhanced the sensitivity of the bioelectranalytical
system, while also improving its accuracy by acting as an inner reference molecule. This system was
first assembled for sensitive and accurate determination of Cu2+, through its electroreduction, by
immobilizing neurokinin B (NKB) for its recognition. Furthermore, due to strong complexation of
Cu2+ with Aβ, Aβ42 could also be detected by the same biosensor as upon its addition, Cu2+ would
be released from the previously formed Cu(NKB)2 complex causing a current signal reduction [45].
For that reason, both Cu2+ and Aβ42 were easily monitored by the same system attaining limits of
detection (LOD) of 0.04 µM and 0.5 ng mL−1, respectively [45]. Despite exhibiting the highest LOD in
Table 1 for Aβ42 determination, Yu et al. [45] were able to verify an increase in the levels of Cu2+ in
plasma of AD rats while attaining recoveries of 97–110% in hippocampus of rats spiked with Aβ42.
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For the determination of Aβ42/Aβ40 levels in cerebrospinal fluid and targeted brain tissue of AD
rats, Yu et al. [46] developed an electrochemical affinity biosensor based on MWCNTs modified with
AuNPs. MWCNTs were implemented with an enhancement role due to their excellent conductivity
and electrochemical activity, causing an increase of the charging currents when compared to the bare
GCE. On the other hand, AuNPs played a dual role by contributing to the enhancement of charging
current while offering a suitable environment for the immobilization of the biological recognition
element, which in this case was a molecular secretory protein with high affinity towards soluble Aβ
peptide designated gelsolin [46]. In this way, the developed electrochemical biosensor was based on a
sandwich-type assay which consisted of a GCE modified with MWCNTs and AuNPs where gelsolin
was further immobilized for the biological recognition process. In addition, a bioconjugate of AuNPs
functionalized with gelsolin and horseradish peroxidase was prepared to complete the sandwich
assay attaining through this process a LOD of 28 pM being the Aβ40 and Aβ42 peptides in a 6:1
concentration ratio [46]. In addition, applying the developed biosensor in real samples it was possible
to observe a clear variation in the CSF and brain tissue levels of Aβ42/Aβ40 between normal and AD
rats. Conversely, even though the developed biosensor was based on a bioreceptor with high affinity
towards Aβ, its capability to distinguish between Aβ42 and Aβ40 was not evaluated. Moreover, the
biosensor was only evaluated for a two-week stability period.
In the last reported study using CNTs for biosensing of AD bio arkers, Lisi et al. [47] developed
a biosensor for tau protein detection using a layer-by-layer approach for a plification of the surface
plas on resonance (SPR) signal (Figure 4). Here, MWCNTs were oxidized in order to overcome
their hydrophobic nature and promote their stability in aqueous solutions in addition to providing
carboxylic groups for their covalent functionalization ith secondary antibodies against tau protein
via a ino coupling reaction. C Ts–antibody conjugate as essential for the achieve ent of the
sand ich bioassay, contributing to the increase of SPR signal by 102 fold hen co pared to direct
detection and conventional unconjugated sand ich (Figure 4). In fact, C Ts functionalized ith
secondary antibodies were used as mass enhancers, providing a consistent refractive index change [47].
Applying this system, and under the optimal conditions, a dose–response relation was displayed,
enabling the determination of tau concentrations in the range 125–1000 pM in which an exponential
behavior was observed while exhibiting good reproducibility and selectivity [47]. Nevertheless, in
order to be applicable in a clinical context, some parameters need to be further evaluated, such as its
stability over time and analytical perfor ance in real samples, as well as lowering the reported LOD.
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2.1.2. Graphene
Graphene is a planar sheet of carbon atoms arranged into a rigid honeycomb structure, and
like CNTs, the carbon bonds are sp2-hybridized [60–65]. As esult f its electron onfiguration,
graphene exhibits large surface area, high mechanical strength, high electrical conductivity, igh
elasticity nd thermal conductivity [60–64,66]. Grap ene oxide (GO) and reduced GO (rGO) re
derivatives of graphene with a vast applicability in the biosensing field (Figure 5 . Graphene can be
easily functionalized into GO ontaining various oxyge functional groups, such as epoxide, carbonyl,
carboxyl nd hydr xyl groups [62,63,66] (Figure 5). These hydrophilic groups mak GO more soluble
in water, while exhibiting better selectivity towards functionalization with biomolecules, which are
highly important features in biosensor application [60,62,63]. On the other hand, rGO is t e form
of GO that is processed by chemical, thermal and other procedures which will ultimately influence
its compo ition and properties [62]. The reduction process will reduce the oxygen content while
introducing structural d fect that will contribute to high thermal conductivity as the electrochemistry
of graphe e sheets occurs at the edges and defects (where heterogeneous electron transfer is fast) and
not at the basal plane [61–63,66] (Figure 5). Usually, rGO presents advantages over graphene and GO
for application in biosensing t chnology as it combines some of the negatively cha ged groups of GO
along with the excellent conductive properties of graphe e [65,67].
Graphene has been used in t ree different ways for th development of electrochemical immuno-
and DNA biosensors for determination of AD biomarkers, namely, Aβ and ApoE, respectively.
Two works performed det rminati n of ApoE thr ugh DNA detection, with Mars et al. [48] using
gra hene quantum dots for a dual biosensing platform with electrochemi al and fluoresc nce
determination, w ile Wu et al. [49] c njugated graphene with mesopor us silica for the development of
a hybrid nanomaterial that served as the basis for ratiometric determi ation. Finally, Kurkina et al. [50]
applied rGO f r the development of a FET el ctrochemical immunosensor for Aβ determinatio .
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ApoE gene, Wu et al. [49] dev loped a ratiometric electroch m al platform based on a GCE modified
with graphene and mesoporous silica hybrid nanom terials (GSHs). Electroactive molecules w th
distinct separate oxidation potentials, specifically methylene blue (MB) and ferroc necarboxylic aci
(Fc), wer emplo ed as the indicato for target and built-in control, respectively. GSHs, produced via a
ducing process with mesoporous silica homogeneously coated on the surface of graphene sheets,
acted a reserv irs for the electroactive MB while the Fc mol cules were covalent y conjugated with
th produc d nanomaterials via a carb iimide-mediated appro h [49]. For the production of the
analytical signal, a duplex DNA probe was firstly immobilized on the GSHs surface, promot by
immobilization of a single-stranded DNA through a 4-maleimidobuty ic aci N-hydroxysuccinimide
(NHS) ester, cag ng the electroactive MB which was only rele sed upon addition of the target DNA
generating a measurable “ -off” cur en [49]. GSHs combined the advantages of both graphene and
mesoporous silica into a single hybrid nanostructure, promot ng a faster e ctron transfer process,
due t its ood condu tivity d large surface area, while encapsulating electroactive molecules [49].
With this electrochemical configuration, ApoE DNA levels as low as 10 fM were able t be determined.
Regarding the det mination of Aβ, Kurkina et al. [50] applied a rGO-FET liquid-gated
configur tio as an electrochemical immunosensor (Figure 6). This work described a chemical
process for the development of a FET device from GO. The procedure involved amino functionalization
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of photolithographically patterned electrodes that reacted with the functional groups on the GO
surface in order to promote its selective immobilization at the electrode locations. GO was then
thermally reduced, displaying a graphene-like field-effect behavior while promoting an appropriate
environment for the biorecognition event [50]. The proper orientation of antibodies against Aβ on
the rGO surface was ensured through its conjugation with Staphylococcus aureus protein A. Applying
impedance spectroscopy analysis and taking advantage of the high sensitivity of rGO to chemical
changes in their surroundings, a 1 fM Aβ concentration was determined [50].
The biosensors developed by Wu [49] and Kurkina [50], despite displaying extremely good
analytical behavior and low LODs, failed to address the parameters of selectivity, reproducibility and
performance in real samples. Moreover, all three reported studies using graphene for the development
of highly sensitive biosensors further need to be evaluated in terms of stability.
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2.2. Nanoparticles
Nanoparticles with varied configurations and properties have been the most frequently used
nanomaterials for the development of novel immuno- and DNA-biosensors [68,69]. Owing to their
small size and high surface area, nanoparticles offer unique chemical, physical and electronic properties
that are advantageous for the development of high-performance biosensors either by using them
as amplifying labels for signal enhancement or by working as an appropriate platform for the
immobilization of biological recognition elements. The most common applied nanoparticles are metal
nanoparticles, which are typically synthesized by chemical reduction of the corresponding transition
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metal salts in the presence of a stabilizer promoting the synthesis of nanoparticles with high stability,
rich linking chemistry and solubility [68–72].
2.2.1. Gold Nanoparticles
Gold nanoparticles (AuNPs) are one of the most frequently applied nanomaterials in the biosensing
field due to their inherent characteristics such as extraordinary optical and electronic properties,
controllable morphology and size, and simple preparation methods [73,74]. In addition, AuNPs exhibit
high chemical stability, excellent conducting capability and catalytic activity, large surface area and
high surface-to-volume ratio, biological compatibility, and ease of functionalization, favoring the
immobilization of biological recognition elements as DNA, antibodies and enzymes [27,32,35,37,73]
(Table 2). These features make AuNPs an outstanding nanomaterial for bridging the biological elements
with the transduction systems [74].
AuNPs have been extensively used for the development of immuno- and DNA-biosensors
for detection of AD biomarkers, being the nanomaterial more frequently reported throughout the
reviewed studies. Being very versatile, AuNPs have been applied with different and complementary
functions, such as promotion of the conductivity and electrochemical activity of the transducer,
immobilization of the biological recognition elements for direct/sandwich detection or conjugated with
other nanomaterials. The most common applications of AuNPs were with self-assembled monolayers
(SAM), either by being deposited on a SAM-modified platform or serving as the platform for promoting
the chemical modification with different SAMs [75–78], and as amplifying agents modified with
secondary antibodies and labels for sandwich immunoassays [46,79–82]. Finally, AuNPs have also been
applied in an isolated manner to transducer surfaces [83–85] or in conjugation with other materials
such as polyethylene glycol (PEG) [86], MWCNTs [46], and ionic liquid [87]. The published studies
clearly acknowledge the vast scope of AuNPs application.
Carneiro et al. [78] developed a label-free electrochemical immunosensor based on AuNP-modified
gold electrode for Aβ42 determination (Figure 7). In this work, the transducer surface was primarily
modified with a mercaptopropionic acid SAM in which AuNPs were electrodeposited. AuNPs
were synthesized and deposited simultaneously by applying a negative potential to the previously
mercaptopropionic acid modified gold electrode while the electrode was in contact with a chloroauric
acid solution. In this study, AuNPs performed a dual role of increasing the electrochemical activity
of the transducer while providing an appropriate environment for the immobilization of antibodies.
It was possible to observe through square-wave voltammetry (SWV) and electrochemical impedance
spectroscopy (EIS) the significant enhancement in the electron transfer process, which had been
greatly hindered after the SAM formation, once AuNPs were electrodeposited [78]. In addition,
chemically modified antibodies were covalently immobilized on the AuNPs surface through thiol groups
introduced into the antibody structure via a thiolation process. With the developed immunosensor,
Aβ42 was determined in the range of 10–1000 pg mL−1 while attaining a LOD of 5.2 pg mL−1 [78].
Further studies concerning selectivity and analytical performance in real samples need to be conducted.
Hu et al. [84] proposed a colorimetric sandwich immunosensor for Aβ42 detection where AuNPs
were individually conjugated with C-terminal antibody and/or N-terminal antibody, to which albumin
from bovine serum was added to minimize non-specific adsorptions [84]. Subsequently, Aβ42 peptide
was simultaneously captured by the previously formed bioconjugates causing the aggregation of
AuNPs, which were accompanied by a color change from red to blue [84]. In this way, taking advantage
of the optical properties of AuNPs and via UV-vis spectrometer analysis, Aβ42 concentrations were
quantified in the range 7.5–350 nM with a LOD of 2.3 nM while displaying good selectivity and
analytical behavior in CSF [84]. On the other hand, further tests concerning the stability parameter
need to be conducted.
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Applying a dual detection platfor , Cheng et al. [85] developed a biosensor to detect D A
hybridization related to a specific point mutation of ApoE (Figure 8). The platform was based on an ITO
modified with electrodeposited AuNPs where DNA probes were immobilized. The electrodeposition
process was carried out through cyclic voltammetry, with all recordings being conducted with a
constant potential range while the ITO surface was immersed in a chloroauric acid solution leading to
the synthesis of AuNPs with 50 to 80 nm. Then, DNA strands were immobilized on the surface of
AuNPs causing a shift in peak wavelength in the localized surface plasmon resonance (LSPR) spectra
as a result of the effective thickness of the adsorbate layer and electromagnetic decay length. LSPR
signal increased in a concentration-dependent manner as target DNA hybridized enabling a 512 nM
LOD [85]. Applying EIS to the detection of DNA hybridization and taking advantage of the high
conductivity of AuNPs, it was possible to attain a LOD of 286 nM as the immobilization of DNA
probe and target led to an increase in the impedance of the platform as a result of the formation of a
biological barrier on the AuNPs surface which hindered the electron transfer process [85]. Regardless
of displaying good LODs and selectivity for LSPR and EIS, further studies need to be conducted in
order to evaluate the reproducibility, stability and analytical behavior in real samples.
Kim et al. [86] developed a shape-code nanoplasmonic biosensor for the determination of three
AD bio arkers. The highly selective biosensor was based on a single platform modified with AuNPs
of different shapes and antibodies that were analyzed through LSPR. Diverse optical properties can
be promoted by the production of AuNPs with different shapes and sizes. As plasmon resonance
wavelength is dependent on shape, size and local refractive index surrounding the nanomaterial,
the synthesis of AuNPs with different shapes and sizes led to the production of nanoparticles
with individual properties that when analyzed through optical spectrometers would function as a
bar-code [86]. Three different types of AuNPs were explored, such as spheres (diameter of 50 nm),
short rods (aspect ratio of 1.6) and long rods (aspect ratio of 3.6) for detection of Aβ40, Aβ42 and Tau
protein, respectively. AuNPs were synthesized via citrate reduction and further modified with PEG
with different molecular weights where the antibody immobilization was promoted via an EDC/NHS
interaction. With this biosensing configuration, and based on its colorimetric features, multiplexed
detection of biomarkers from a single sample was performed, attaining LODs of 34.9 fM, 26 fM and
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23.6 fM for detection of Aβ40, Aβ42 and tau protein, respectively [86]. The work developed by
Kim et al. [86] was the only one to simultaneously and separately determine three of the most important
AD biomarkers with extremely low LODs in addition to successfully measure their levels in samples
of human plasma. Nonetheless, studies concerning the biosensor’s stability still need to be conducted.
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2.2.2. Other Nanoparticles
AgNPs [88], magnetic nanoparticles [82,89,90] and QDs [48,90] have also been used in the
development of biosensors for AD diagnosis but to a lesser extent (Table 2).
Presenting characteristics of noble metals such as high conductivity, enhanced electrochemical
signal and excellent biocompatibility, AgNPs and their composites have also been explored for the
development of biosensing platforms for the determination of several analytes [27,35,91]. In a study
developed by Hu et al. [88], a colorimetric immunosensor based on silver nanoparticles was developed
for quantification of the Aβ40/Aβ42 ratio (Figure 9), following a similar procedure as the one based
on AuNPs for Aβ42 [84]. In this work, the biosensor was based on the interaction between Aβ and
Cu2+, using AgNPs conjugated with C-terminal antibodies. In the presence of Cu2+ and Aβ40/Aβ42
(ratio of 6:1), the conjugate antibody-AgNPs showed high sensitivity towards the analytes of interest
leading to the aggregation of modified AgNPs upon binding between Aβ and Cu2+, which was
accompanied with color change from yellow to red (Figure 9). Through absorbance determination,
the immunosensor displayed better sensitivity and selectivity than the previously reported study
as a result of AgNPs properties, including distance-dependent color and high extinction coefficient,
attaining a LOD of 86 pM [88]. In addition, the colorimetric immunosensor was successfully applied in
spiked blood samples.
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Magnetic nanoparticles have been the focus of a vast number of studies as a result of their
special properties, which include ease of size control, low-cost production, physico-chemical stability,
biocompatibility and easy manipulation with magnetic fields, and they are applied in a broad range
of biomedical areas as cell labeling, medical imaging, drug delivery, hyperthermia treatment and
biosensing [32,35,37,92,93]. Magnetic nanoparticles can be classified as metals, alloys or oxides and
are generally based on elements such as iron, cobalt, nickel or manganese, among others [32,93].
These nanoparticles exhibit magnetic behaviors that can be influenced by their small size and shape [32].
When small enough, magnetic nanoparticles can express a superparamagnetic behavior, meaning that
magnetization can randomly flip direction under the influence of temperature on reduced time periods,
called Neel’s relaxation time [32,37]. This temperature effect disappears in the presence of an external
magnetic field becoming magnetized and aligned with the direction of the field but magnetization
appears on average zero once the external field is removed [32,37]. Such superparamagnetic behavior
prevents agglomeration of the nanoparticles in the absence of a magnetic field, which becomes
particularly relevant in specific applications such as magnetic hyperthermia [32]. Moreover, these
nanoparticles must be functionalized with hydrophilic and biocompatible coating to prevent aggregation
in aqueous solutions while providing a suitable matrix for immobilization of biological recognition
elements [32,37].
De la Escosura-Muñiz [82] developed a biosensor based on a magneto sandwich immunoassay
using porous magnetic microspheres (PMMs) as platforms for the recognition event of Aβ and
ApoE from human samples. AuNPs were further applied as electrocatalytic agents to complete the
sandwich immunoassay and obtain the analytical signal. PMMs were prepared by a multistep swelling
polymerization with iron oxide precipitation and combining their high functionality with their large
porosity, PMMs offered a high active area that allowed the efficient capture of the target analytes while
promoting an enhanced catalytic activity of AuNPs [82]. Antibodies were covalently immobilized on
the PMMs surface via EDC chemistry between the carboxylic groups of PMMs and antibody amine
groups while the secondary antibodies were randomly adsorbed on the AuNPs surface. The magnetic
conjugate was further immobilized on the surface of a screen-printed carbon electrode focusing the
electrochemical determination of AD biomarkers on the electrocatalytic behavior of AuNPs towards
the hydrogen evolution reaction, which through chronoamperometry attained LODs of 19 pg mL−1 and
80 pg mL−1 for determination of Aβ and ApoE, respectively [82]. Taking advantage of the excellent
structure of PMMs for antibody immobilization, the developed immunosensor was successfully applied
in real clinical CSF, serum and plasma samples of patients suffering from AD. Rivas et al. [89] explored
the excellent electrocatalytic activity of iridium oxide nanoparticles towards the water oxidation reaction
and employed this as a new signaling mechanism in protein diagnosis (Figure 10). The procedure is
similar to that previously described by de la Escosura-Muñiz [82] but, instead of AuNPs, the team used
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iridium oxide nanoparticles. Magnetic beads were modified with antibodies and applied as platforms
for immunoassay detection of ApoE [89]. Therefore, antibodies were immobilized on the magnetic
beads surface through EDC chemistry while the immobilization of secondary antibodies on iridium
oxide nanoparticles was performed by direct random adsorption. The immunocomplex was formed in
solution, taking advantage of the great properties of magnetic beads for capturing the analyte and
minimizing matrix effects [89]. Then, the secondary antibodies-iridium oxide nanoparticles conjugate
was able to recognize ApoE, completing the magneto sandwich immunoassay [89]. Finally, the
sandwich immunocomplex was immobilized on the surface of a screen printed carbon electrode where
the catalytic activity of the iridium oxide nanoparticles was monitored through chronoamperometry
enabling the quantification of ApoE concentration in the range 100–1000 ng mL−1 with a 68 ng mL−1
LOD in addition to performing ApoE detection in human plasma [89]. The detection based on water
oxidation reaction is a simple and sensitive methodology that opens the possibilities for further
applications in integrated systems such as those based on lab-on-chip or lateral flow platforms.
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Medina-Sánchez et al. [90] developed an on-chip magneto-immunoassay for ApoE via 
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diseases [37,95]. Nonetheless, QD surfaces can be diversely modified either through conjugation with
other semiconducting materials with wider band gaps in order to passivate structural defects and
enhance quantum yields and photo-stability or with inert and biocompatible coatings to reduce any
possibility of toxicity and promote their functionalization with biological recognition elements [32,37,94].
Therefore, Medina-Sánchez et al. [90] developed an immunocomplex based on a microfluidic chip
with integrated screen-printed electrodes functionalized with magnetic beads and using QDs as
amplifying agents. Firstly, magnetic beads functionalized with antibodies were immobilized on
the working electrode through a neodymium magnet placed underneath the substrate. Then, the
analyte was flushed through the magnetic beads at different concentrations, followed by detection of
biotinylated secondary antibodies. Finally, streptavidin-QDs were introduced to complete the sandwich
immunoassay. Electrochemical detection of CdSe@ZnS QDs was conducted through square-wave
anodic stripping voltammetry which produced an analytical signal from the reduction of Cd2+ to
Cd and its further reoxidation [90]. The QDs concentrations were directly related to the levels of
ApoE enabling its determination in the range 10–200 ng mL−1 with a 12.5 ng mL−1 LOD along with
performing its detection in human plasma [90]. The use of pH 3.0 buffer in the last step to perform
the measurements led to a degradation of the microfluidic platform and SPCE after 15 measurements
which makes this platform unreliable for repeated measurements.
Table 2. Biosensors based on nanoparticles (AuNPs, AgNPs and magnetic particles) for the
determination of AD biomarkers.
Transducer DetectionTechnique Analyte Sample
Limit of Detection
(nM *) Ref.
Gold Nanoparticles
SPCE/AuNPs/PEG-MPA/Antibodies/
Analyte/Secondary antibodies-ALP DPV Aβ42
Buffer, human serum
and Plasma 1 × 10−4 [75]
Carbon printed chip/AuNPs/MHDA
SAM/Protein G/Antibodies EIS Aβ42 Buffer 0.57 [76]
AAO/Au film/AuNPs/MUA
SAM/Antibody EIS Aβ42 Buffer 2.2 × 10−6 * [77]
AuE/MPA SAM/AuNPs/Antibodies SWV Aβ42 Buffer 1.15 × 10−3 * [78]
Silicon Wafer/Au/ODT
SAM/Antibody
fragments/Analyte/AuNPs-antibodies
STM Aβ42 Buffer 2.2 × 10−6 * [79]
AuE/MPA
SAM/Antibodies/Analyte/
Aptamer-CS-AuNPs conjugate
DPV Tauprotein-381
Buffer and Human
serum 4.2 × 10−4 [80]
AuE/MPA
SAM/Antibodies/Analyte/
Aptamer-CS-AuNPs conjugate
DPV Tauprotein-381
Buffer and Human
serum 4.2 × 10−4
AuE/MPA
SAM/Antibodies/Analyte/
Aβ(1–16)-heme-AuNPs
CV Aβ40/Aβ42 Buffer and aCSF 0.01 [81]
SPCE/AuNPs/Analyte/
Antibodies/ALP-Antibodies CV Aβ42 Buffer 0.022 * [83]
AuNPs/Antibodies/Analyte ColorimetricUV-Vis Aβ42
Buffer and Serum
samples 2.3 [84]
ITO/AuNPs/Oligonucleotides LSPR and EIS ApoE DNA Buffer LSPR: 512EIS: 286 [85]
Glass/APTES/PEG-AuNPs/Antibodies LSPR
Aβ40
Aβ42
Tau Protein
Dulbecco’s PBS mixed
with human plasma
samples
Aβ40 3.49 × 10−5;
Aβ42 2.6 × 10−5;
Tau protein 2.36 × 10−5
[86]
ITO/APTMS/Glutaraldehyde/Ionic
Liquid (BMIMBF4)/Chitosan/
AuNPs/Antibodies/Analyte/
Au-TiO2/GOx/Antibodies
Colorimetric ApoE Buffer and Serum 1.2 × 10−5 * [87]
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Table 2. Cont.
Transducer DetectionTechnique Analyte Sample
Limit of Detection
(nM *) Ref.
Silver Nanoparticles
AgNPs/Antibodies ColorimetricUV-Vis Aβ40/Aβ42
Buffer and Human
blood serum 0.086 [88]
Magnetic Nanoparticles
SPCE/PMMs/Antibodies/
Analyte/AuNPs-antibodies Chronoamperometry
Aβ
ApoE
Buffer, CSF, serum and
plasma samples of AD
patients
Aβ 4.2 × 10−3 *
ApoE 2.4 × 10−3 * [82]
SPCE/MB/Antibodies/
Analyte/IrO2
nanoparticles-secondary antibodies
Chronoamperometry ApoE Buffer and Humanplasma 2 * [89]
Graphite ink (microfluidic
platform)/MB/Antibodies/
Analyte/Antibodies/QDs
SWASV ApoE Buffer and humanplasma 0.37 * [90]
* Value expressed in µg mL−1, ng mL−1 or pg mL−1 and converted to nM. AAO, Anodic aluminium oxide; aCSF,
Artificial cerebrospinal fluid; AD, Alzheimer’s disease; AgNPs, Silver nanoparticles; ALP, Alkaline phosphatase;
APTES, 3-aminopropyltriethoxysilane; APMS, 3-aminopropyltrimethoxysilane; AuE, Gold electrode; AuNPs,
Gold Nanoparticles; CSF, Cerebrospinal fluid; CS, Cysteamine; CV, Cyclic voltammetry; DPV, Differential pulse
voltammetry; EIS, Electrochemical impedance spectroscopy; GOx, Glucose oxidase; ITO, Indium tin oxide;
LSPR, Localized surface plasmon resonance; MB, Magnetic beads; MHDA, 16-mercaptohexadecanoic acid; MPA,
Mercaptopropionic acid; MUA, 11-mercaptoundecanoic acid; ODT, 1,8-Octanedithiol; PBS, Phosphate buffer saline;
PEG, Polyethylene glycol; PMMs, Porous magnetic microspheres; QDs, Quantum dots; SAM, Self-assembled
monolayer; SPCE, Screen-printed carbon electrode; STM, Scanning tunnelling microscopy; SWASV, Square-wave
anodic stripping voltammetry; SWV, Square-wave voltammetry.
2.3. Polymer Nanomaterials
Polymers, both natural and synthetic, have been widely used for the development of biosensing
platforms due to their easy functionalization and long-term stability [35]. Natural materials, of plant
and animal origin, exhibit important characteristics, such as biocompatibility, bioactivity and possibility
of biodegradation, allowing them to be successfully applied at a clinical level [96]. On the other hand,
the use of synthetic polymers has become an integral component of our everyday life as a result of
their chemical resistance, tunable properties and mechanical durability [97].
Biosensing technology based on polymer nanomaterials has been commonly employed due
to their easy functionalization with biomolecules, high sensitivity and selectivity, hysteresis, and
long-term stability [35]. The most common polymeric materials used for the development of biosensing
technology for determination of AD biomarkers, through DNA and antigens detection, have been
based on homo- and co-polymers [86,98–102], as well as conducting polymers (CPs) [103] (Table 3).
A label-free impedimetric biosensor was proposed by Rushworth et al. [99] for determination
of Aβ oligomers based on screen-printed gold electrodes (SPGE) modified with co-polymer of
polytyramine/3-(4-hydroxyphenyl) propionic acid. Using a layer-by-layer approach, the selected
co-polymer was electropolymerized on the surface of the SPGE followed by conjugation of the biological
recognition element via a biotin/neutravidin interaction [99]. The biological recognition element used
in this work was the fragment of the cellular prion protein (PrPc, residues 95–110), a highly expressed
synaptic protein, which mediates the neuronal binding and toxicity of Aβ oligomers [99]. In this
work, poly(tyramine) was conjugated with 3-(4-hydroxyphenyl) propionic acid to favor the presence
of negatively charged groups that contributed to minimize the non-specific binding of molecules [99].
Through EIS, Aβ oligomers levels were able to be determined in the range 10−6–10−12 M, attaining a
LOD of 0.5 pM [99]. The developed biosensor presented the advantage of being a label-free detection
system capable of distinguishing between Aβ monomers and oligomers at an Aβ concentration of
100 pM. Even so, this study still needs to be further validated in real samples.
Conducting polymers have also been applied towards the development of biosensing platforms
taking advantage of their high surface area, small dimensions, inherent electrical conductivity and
unique physical properties, while also having potential applicability in flexible/wearable electronics in
which conducting polymers can display a flexible organic conductor or semiconductor behavior [35,
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104,105]. In this way, Qin et al. [103] developed a biosensor for monitoring early diagnosis of AD
through Aβ oligomers determination based on the electrically conducting poly(pyrrole-2-carboxylic
acid) (PPy) and using PrPc as the biological recognition element. The linking agents that promote the
immobilization of PrPc on the transducers surface are relatively big molecules that can hinder the
electron transfer process, causing significant resistance and, ultimately, compromising the detection
of Aβ oligomers at low levels [103]. Therefore, conductive PPy containing carboxylic groups was
electrochemically deposited on a gold surface in order to ensure a good electrochemical behavior
of the transducer by scanning the electrode from −0.3 to 1.5 V [103]. For immobilization of the
biological recognition elements, PrPc was amine functionalized and added to the previously activated
PPy modified gold electrode. With the proposed biosensor, Qin et al. [103] were able to attain a
10−4 pM LOD while quantifying Aβ oligomers concentrations in the range 10−7–10 nM, proving the
excellent properties of PPy as an electroactive material and bioreceptor [103]. This study exhibited an
exceptionally low LOD (while attaining recoveries of 98–116% in brain samples), a clear selectivity
towards Aβ oligomers (when compared with Aβ monomers and fibrils) and high stability after one
month at 4 ◦C.
Table 3. Biosensors-based polymers for determination of AD biomarkers.
Transducer DetectionTechnique Analyte Sample
Limit of
Detection (nM *) Ref.
Homo- and co-polymers
Silicon
platform/poly(DMA-co-NAS-co-MAPS)
/Antibodies/Analyte/Secondary
Antibodies/Cyanine 3
Fluorescent
detection Aβ42 aCSF 0.016 * [98]
SPGE/POPA co-polymer/PrPC (95–110) EIS Aβ oligomers
DMSO/F12 medium
and Chinese hamster
ovary cell line
5 × 10−4 [99]
Interdigitated
microelectrode/SiO2/APMES/Polyvinyl
pyrrolidone-aldehyde solution/Sodium
borohydride/Glutaraldehyde/Antibodies
Impedance Aβ42 Buffer and mouseplasma 2.2 × 10−5 [100]
Ion concentration polarization-based
preconcentration-Interdigitated
microelectrode/SiO2/APMES/Polyvinyl
pyrrolidone-aldehyde solution/Sodium
borohydride/Glutaraldehyde/Antibodies
Impedance Aβ42 Buffer 8.15 × 10−6 [101]
Glass slides/Au film/SAM of carboxyl-
and hydroxyl-terminated
PEG/Antibodies/Analyte/Antibody
SPR Aβ40/Aβ42 Buffer and CSF 0.02 [102]
Conducting Polymers
AuE/Poly (pyrrole-2-carboxylic
acid)/PrPC EIS Aβ oligomers
Buffer and Brain
samples 10
−7 [103]
* Value expressed in µg mL−1/ng mL−1/pg mL−1 and converted to nM. aCSF, Artificial cerebrospinal fluid; APMES,
3-(ethoxydimethylsilyl) propylamine; AuE, Gold electrode; CSF, Cereborspinal fluid; DMSO, Dimethyl sulfoxide; EIS,
Electrochemical impedance spectroscopy; PEG, Polyethylene glycol; poly(DMA-co-NAS-co-MAPS), Ter-copolymer
made with an optimized composition of dimethylacrylamide (DMA), 3-(trimethoxysilyl)propyl methacrylate (MAPS)
and N-Acryloyloxy succinimide ester (NAS); POPA, Co-polymer of polytyr-amine/3-(4-hydroxyphenyl) propionic
acid; SAM, Self-assembled monolayer; SPGE, Screen-printed gold electrode; SPR, Surface plasmon resonance.
3. Future Perspectives
An early assessment of changes in AD biomarker levels is an essential contribution to informed
decisions and the conception of better treatment plans, in addition to increasing the possibilities of
success of disease-modifying drugs [10,13,106,107]. Nowadays, three core AD CSF biomarkers have
proven diagnostic accuracy for mild cognitive impairment and dementia due to AD, namely Aβ42,
total tau, and tau phosphorylated at threonine 181 [10,13,107]. Growing evidence supports the use of
the concentration ratio of Aβ42 to Aβ40 as an analytical parameter to improve the accuracy of AD
diagnosis when compared to isolated determination of Aβ42, with its main disadvantage being related
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to an increase in the costs of analysis [13]. In addition, both CSF total and phosphorylated tau are
essential for a differential AD diagnosis, underlining the role of phosphorylated tau, since its levels in
other dementias are normal [10].
Based on this review, it is possible to outline some serious challenges concerning the development
of biosensing platforms in a routine and scalable manner as these devices usually struggle with stability
and reproducibility issues when applied to biological samples. In addition, only some studies used
real samples obtained from AD patients, with most biosensors being tested in buffer, artificial samples,
or real samples spiked with the analytes of interest. On the other hand, the studies that applied the
developed biosensors in real samples were able to recognize a clear difference in protein levels between
AD and normal individuals [45,46,102,103]. Moreover, particularly in the case of AD, multiplexing
detection is a crucial point that is still lacking, since this disease arises from a combination of multiple
pathological pathways, ideally requiring the detection of a group of biomarkers in order to ensure a
sensitive and accurate diagnosis. Nanomaterials are playing a pivotal role in solving these problems,
as nanomaterials with varied sizes display different properties, which translates into differentiated
electrochemical and optical behaviors that in turn, when conjugated with specific biological recognition
elements, can contribute to differentiated diagnosis.
4. Conclusions
The aging of the world’s population is directly related to the increase in the prevalence of AD, as
this disease frequently manifests in the late stages of life. In addition, this neurological disorder can
impose a great financial burden on society, as this condition extends through years, highlighting AD as
one of the biggest medical and societal challenges of this century. Therefore, there is an urgent need for
the development of diagnostic tools that will contribute to more accurate and sensitive diagnosis in
the earlier stages of the disorder, also giving a better chance to therapeutics of slowing or stopping
disease progression. During the last decade, significant efforts were done towards the development of
immuno- and DNA-biosensors for the determination of AD main biomarkers. Sensitivity, selectivity,
stability, speed, simplicity and cost benefits continue to be the main parameters for ensuring the quality
and performance requirements for the development of novel diagnostic technologies. In this way, the
synergy between nanomaterials, biological recognition elements and different transduction techniques
has been contributing for the development of biosensors that meet the required parameters. In fact, the
outstanding advances in nanotechnology, namely in the synthesis and production of a vast number of
nanomaterials, has led to striking developments in the biosensing field. Biosensing platforms coupled
with nanostructures not only exhibit a better electrochemical and optical behavior as they also provide
an appropriate and biocompatible environment for the immobilization of recognition elements, which
is a crucial stage in the development of immuno and DNA biosensors. Thus, throughout this review,
the crucial functions that nanomaterials have adopted in the development of biosensing platforms
when coupled with different transduction structures were addressed. The most commonly reported
nanomaterials for the development of biosensing platforms were AuNPs, carbon nanomaterials (CNTs
and graphene), and polymers, and these displayed a variety of functions, but most frequently that
of contributing to the enhancement of the biosensor performance due to their excellent conductive
and optical properties, which in conjunction with their ease of functionalization promoted stable and
oriented immobilization of antibodies and DNA strands on the nanomaterials surface. In addition,
nanomaterials were also commonly used as amplifying agents, usually modified with secondary
recognition elements and labels, to perform indirect detection of target proteins, which can also
contribute to more sensitive and selective analytical procedures.
Apart from the increasing relevance achieved by nanomaterials in the development of immuno-
and DNA-biosensors with enhanced performance, there are still some important challenges to overcome
before commercialization of biosensing devices with clinical application becomes a reality.
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